Study Number	Completed Clinical Trial Report Summaries
3591IL/0079	Meropenem I.V. (ICI 194,660) versus Imipenem-Cilastatin for the Treatment of Hospitalized Patients with Complicated Skin and Skin Structure Infections: Results of a Multicenter, Randomized, and Double-Blind Comparative Study (3591IL/0079).
3591IL/0091	An Open-label Study to Determine the Concentration of Meropenem in Plasma and Cantharidin-induced Skin Blister Fluid Following Repeated Intravenous Infusion of Meropenem 500 mg Every 8 Hours in Healthy Males
3591US/0020	Multicenter Nonrandomized Trial of Intravenous MERREM™ (Meropenem, ICI 194,660) for the Treatment of Hospital-Acquired Pneumonia
3591US/0022	A Multicenter, Randomized, Open-label Trial of MERREM™ I.V. (meropenem, ICI 194,660) and PRIMAXIN® I.V. (imipenem/cilastatin) for the Treatment of Community-acquired Bacterial Pneumonia.
3591US/0031	A Study to Assess the Concentration of Meropenem in Epithelial Lining Fluid, Pulmonary Alveolar Cells, and Plasma Following the Intravenous Administration of Multidoses to Healthy Subjects
3591/SWNU	Withholding initial vancomycin in febrile neutropenia despite implanted catheters
3591/9002	Observational, prospective, comparative study of the efficacy and tolerability of meropenem in the treatment of febrile episodes in neutropenic patients older than 64 years old (or younger than 65 years old but with renal insufficiency) with that of patients younger than 65 years old but with normal renal function.
3591/9006	The initial empiric antibiotic treatments in childhood febrile neutropenia: meropenem versus ceftazidime plus amikacin combination
3591/9007	Convulsion rates in patients treated with carbapenems in stem cell transplants
3591/9014	Pharmacoeconomic analyses of first line meropenem versus standard antibiotic treatment in secondary nosocomial sepsis syndrome patients. An open, randomised multi-centre study.
3591/IN01	Use of meropenem in the treatment of moderate and serious infections (An open, non-comparative, multicentre, post marketing surveillance study)